June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Structural biomarkers of abnormal dynamic and static rod function in the MACUSTAR baseline dataset
Author Affiliations & Notes
  • Alison Binns
    School of Health and Psychological Sciences, City, University of London, London, United Kingdom
  • Hannah M P Dunbar
    University College London, London, London, United Kingdom
    Moorfields Eye Hospital NHS Foundation Trust, London, London, United Kingdom
  • David Crabb
    School of Health and Psychological Sciences, City, University of London, London, United Kingdom
  • Charlotte Behning
    Institute of Medical Biometry, Informatics and Epidemiology, Medical faculty, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Jan H. Terheyden
    department of ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Marlene Sassmannshausen
    department of ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • sarah thiele
    department of ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Steffen Schmitz-Valckenberg
    department of ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
    John A. Moran Eye Center, University of Utah Health, Salt Lake City, Utah, United States
  • Bethany Elora Higgins
    School of Health and Psychological Sciences, City, University of London, London, United Kingdom
  • Stephen Poor
    Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, United States
  • Robert Patrick Finger
    department of ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Sergio Leal
    Bayer AG, Leverkusen, Nordrhein-Westfalen, Germany
  • Frank G Holz
    department of ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Matthias Schmid
    Institute of Medical Biometry, Informatics and Epidemiology, Medical faculty, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Ulrich F O Luhmann
    F Hoffmann-La Roche AG Research and Development Division, Basel, Basel-Stadt, Switzerland
  • Footnotes
    Commercial Relationships   Alison Binns Patent number: 9492081, Code P (Patent); Hannah Dunbar Boehringer Ingelheim, Code C (Consultant/Contractor); David Crabb AbbVie/Allergan, Apellis, Janssen, Code C (Consultant/Contractor), AbbVie/Allergan, Apellis, Santen, Code F (Financial Support), AbbVie/Allergan, Santen, Thea, Glaukos, Code R (Recipient); Charlotte Behning None; Jan Terheyden Carl Zeiss MedicTec, CenterVue, Heidelberg Engineering, Optos, Code F (Financial Support), Novartis, Okko , Code R (Recipient); Marlene Sassmannshausen Heidelberg Engineering (F), CenterVue, Carl Zeiss MedicTec, Code F (Financial Support); sarah thiele Carl Zeiss MedicTec AG, CenterVue, Heidelberg Engineering, Optos, Novartis, Code F (Financial Support), Allergan, Bayer, Heidelberg Engineering, Novartis, Code R (Recipient); Steffen Schmitz-Valckenberg AlphaRET, Apellis, Bioeq, Katairo, Kubota Vision, Novartis, Pixium, Roche, SparingVision, Code C (Consultant/Contractor), Bayer, Carl Zeiss MediTec, Heidelberg Engineering, Novartis, Roche, Code F (Financial Support), STZ GRADE Reading Center, Code O (Owner), Apellis, Heidelberg Engineering, Code R (Recipient); Bethany Higgins None; Stephen Poor Novartis Institute for Biomedical Research , Code E (Employment); Robert Finger Alimera, Apellis, Bayer, Böhringer-Ingelheim, Novartis, ODOS, Oxford Innovation, ProGenerika, Roche/Genentech, Code C (Consultant/Contractor), Biogen, CentreVue (now Icare), Heidelberg Engineering, Zeiss Meditec, Code F (Financial Support); Sergio Leal Bayer Consumer Care AG, Code E (Employment); Frank Holz Zeiss, Stealth BioTherapeutics, Oxurion, Pixium Vision, Novartis, LinBioscience, Kanghong, Janssen, IvericBio, Heidelberg Engineering, Gyroscope, Graybug, Geuder, Roche/Genentech, Bioeq/Formycon, Boehringer-Ingelheim, Bayer, Astellas, Apellis, Alzheon, Alexion, Acucela, Code C (Consultant/Contractor), Zeiss, Pixium Vision, Optos, Novartis, NightStarX, Kanghong, IvericBio, Heidelberg Engineering, Geuder, Roche/Genentech, CenterVue, Bioeq/Formycon, Bayer, Apellis, Allergan, Acucela, Code F (Financial Support), GRADE Reading Center, Code O (Owner); Matthias Schmid None; Ulrich Luhmann F. Hoffmann-La Roche Ltd , Code E (Employment)
  • Footnotes
    Support  Innovative Medicines Initiative (IMI) Grant agreement number 116076
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2763. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alison Binns, Hannah M P Dunbar, David Crabb, Charlotte Behning, Jan H. Terheyden, Marlene Sassmannshausen, sarah thiele, Steffen Schmitz-Valckenberg, Bethany Elora Higgins, Stephen Poor, Robert Patrick Finger, Sergio Leal, Frank G Holz, Matthias Schmid, Ulrich F O Luhmann; Structural biomarkers of abnormal dynamic and static rod function in the MACUSTAR baseline dataset. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2763.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine whether structural biomarkers of age-related macular degeneration (AMD) vary between those with ‘normal’ and ‘abnormal’ rod function in the MACUSTAR baseline dataset.

Methods : Subjects with early(e) and intermediate(i) AMD underwent baseline tests including mesopic and scotopic fundus-controlled perimetry average threshold (mAT and sAT; icare), dark adaptation rod intercept time (RIT; AdaptDX), and multimodal imaging. Functional data were dichotomized against one-sided normal reference limits (95th/5th percentile) defined for each test based on MACUSTAR no AMD cross-sectional data. Proportions of people showing specific structural markers of AMD (pigmentary abnormalities, reticular pseudodrusen [RPD], incomplete/complete retinal pigment epithelial and outer retinal atrophy [iRORA/cRORA]) were compared between those with ‘normal’ and ‘abnormal’ function.

Results : From 620 subjects [eAMD (n=34), iAMD (n = 586)] who completed the baseline visit, 447 RIT (72%), 589 mAT (95%) and 564 (91%) sAT tests were valid. In pooled valid eAMD/iAMD data, 187 (42%) RIT, 127 (22%) mAT, and 116 (21%) sAT tests were abnormal (proportion higher for RIT than for either mAT or sAT [p<0.0001]). This remained the case when abnormal results were considered as a proportion of 619 total possible tests (30% RIT, 20% mAT, 19% sAT, p<0.0001). There was no significant difference in the proportion of abnormal tests between mAT and sAT (p>0.05). 417 participants produced a valid result for all three tests, of which 187 (45%) were normal and 35 (8%) abnormal for all 3 tests. 111 (27%), 13 (3%) and 16 (4%) were abnormal for RIT, mAT or sAT only, respectively, and 28 (7%) were abnormal for both mAT and sAT. A higher proportion of those with abnormal RIT (39%) than normal RIT (15%) had RPD (p<0.0001). Being abnormal for mAT or sAT was associated with increased prevalence of RPD, iRORA, cRORA and refractile deposits (p<0.05). sAT abnormality was also associated with increased prevalence of pigmentary abnormality (p=0.02).

Conclusions : Presence of e/iAMD was more strongly associated with a deficit in dynamic rod function (RIT) than static functional measures (mAT and/or sAT); there was no significant difference between mAT and sAT. The presence of RPD was strongly associated with abnormal function in all three tests, whilst other structural biomarkers were associated only with abnormality in the static functional tests.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×